SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: NotAsBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 5/26/2017 12:44:18 PM - Followers: 715 - Board type: Free - Posts Today: 36

Cellceutix Corporation (CTIX)
 

http://cellceutix.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com

 
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly-traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Cellceutix's psoriasis drug candidate Prurisol completed a Phase 2 trial and Cellceutix recently launched a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at www.cellceutix.com.

Management:  http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.cellceutix.com/therapeutic-areas/

 

PIPELINE:

 

FDA DESIGNATIONS:

 

COMPLETED/UPCOMING MILESTONES:



Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines
http://www.cellceutix.com/press-release/

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 
info@cellceutix.com

http://www.cellceutix.com/new-faq/


Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
CTIX News: Quarterly Report (10-q) 05/09/2017 04:09:09 PM
CTIX News: Amended Statement of Ownership (sc 13g/a) 04/28/2017 12:50:45 PM
CTIX News: Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance 04/17/2017 07:03:27 AM
CTIX News: Current Report Filing (8-k) 03/31/2017 04:25:24 PM
CTIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 03/29/2017 04:13:08 PM
PostSubject
#182860  Sticky Note B-UP Due Diligence (Rev. 5/22) sox040713 05/22/17 03:11:36 PM
#182459  Sticky Note Good NEWS...Cellceutix Completes Patient Enrollment of Final Cohort TheDane 05/18/17 09:40:08 AM
#180448  Sticky Note PART II *** Please Read DaubersUP 04/28/17 12:59:51 PM
#175709  Sticky Note CTIX Milestones, Clinical Trials, Recent Interviews, Fact Sheets sox040713 03/18/17 06:44:12 PM
#174938  Sticky Note B-UP Due Diligence (Rev. 3/10) sox040713 03/10/17 04:08:53 PM
#183385   hound, who is PUMA? a brokerage house? I 1hb 05/26/17 12:44:18 PM
#183384   ask is holding tight. PUMA's pushing a large TheHound 05/26/17 12:39:52 PM
#183383   did adam tweet or negative seeking alpha article 1hb 05/26/17 12:39:00 PM
#183382   LOL - Roses are red, Violets are blue, wildtp 05/26/17 12:38:02 PM
#183381   WOW! MAXFUD is bearish on CTIX today! WTF! wildtp 05/26/17 12:29:07 PM
#183380   Yup, just in the last half hour. BooDog 05/26/17 12:27:04 PM
#183379   Volume picked up considerably on the down swing north40000 05/26/17 12:25:18 PM
#183378   Is this still real trading or back to scottsmith 05/26/17 12:24:17 PM
#183377   Notice the drop off on volume while this BooDog 05/26/17 11:57:14 AM
#183375   Glad to see u back too KMBJN - slcimmuno 05/26/17 11:28:52 AM
#183374   and there it is - the 90's. MXAMDUD 05/26/17 11:25:40 AM
#183372   It would have been a bad idea to septmike09 05/26/17 10:56:12 AM
#183371   Smart ctix analysis that this board needs scottsmith 05/26/17 10:55:57 AM
#183370   Do you work for a firm that tries Focusakker 05/26/17 10:53:16 AM
#183369   Glad to see you back posting interesting things KMBJN 05/26/17 10:51:44 AM
#183368   that is Leo's fault for failure to uplist MXAMDUD 05/26/17 10:36:14 AM
#183367   Thanks so much Cabel. wild4ctix 05/26/17 10:22:40 AM
#183366   Nothing like splitting a penny 10 ways for Vlady 1 05/26/17 10:10:39 AM
#183365   Leo has the link below...K + this technology north40000 05/26/17 09:35:57 AM
#183364   Wouldn't the Big wealthy pharmaceutical companies pay for alwaysdreaming 05/26/17 09:19:31 AM
#183363   unfortunately this bounce has been nothing but a MXAMDUD 05/26/17 09:15:50 AM
#183362   I saw it here... I think it was cabel 05/26/17 09:13:44 AM
#183361   Good find - def looking fwd to seeing slcimmuno 05/26/17 09:11:50 AM
#183360   I sent it off to Leo after I cabel 05/26/17 08:51:47 AM
#183359   Does it really matter unless you plan to petemantx 05/26/17 08:47:51 AM
#183358   New CTIX blog piece - nice to see slcimmuno 05/26/17 07:44:26 AM
#183357   ...neither Justfactsmam 05/26/17 07:30:04 AM
#183356   Up or down today? snayeman 05/26/17 07:19:26 AM
#183355   The target end date you mention is untrue. steppe 05/26/17 06:59:00 AM
#183354   heard prurisol target end date is 7-1-17 untohim 05/26/17 05:57:55 AM
#183353   She said she was from Michigan I believe untohim 05/26/17 05:56:23 AM
#183352   imo sounded like an enrollee in the prurisol untohim 05/26/17 05:29:28 AM
#183351   11-12 July 2017 Clinical Operationsa in Oncology Trials georgejjl 05/26/17 02:27:40 AM
#183350   CTIX is the #1 stock to own in georgejjl 05/26/17 02:16:10 AM
#183349   Since Kevetrin has the ability to chemosensitize, its sox040713 05/25/17 11:47:13 PM
#183342   Thanks for letting psoriasis sufferers know about the nerby 05/25/17 08:23:58 PM
#183338   Prurisol alone is worth at least $10 billion!!! georgejjl 05/25/17 07:57:02 PM
#183337   Mind reader. It's like you're right here with me. G Bert 05/25/17 07:50:28 PM
#183334   Hopefully the author informed the audience that Prurisol scottsmith 05/25/17 07:01:45 PM
#183332   Did you mean "asset" or "asshat"...thought maybe you wildtp 05/25/17 06:48:11 PM
#183331   FINRA short sales of CTIX AlanC 05/25/17 06:16:21 PM
#183330   A frequent poster to this board has been nerby 05/25/17 05:47:08 PM
#183329   I forget sometimes people can't see my eyes G Bert 05/25/17 04:34:19 PM
#183328   G Bert, you are pulling his leg right? taas 05/25/17 04:18:33 PM
#183327   ask you shall receive MXAMDUD 05/25/17 04:02:35 PM
#183326   Someone tried to paint a $1.03 close but TheDane 05/25/17 04:01:03 PM
#183325   Yes indeed! TheDane 05/25/17 03:34:13 PM
#183324   Keep up the great work. What an asset G Bert 05/25/17 03:10:47 PM
#183323   will do. I will make it close MXAMDUD 05/25/17 02:46:52 PM
#183322   But you have the ability to change that. G Bert 05/25/17 02:41:43 PM
PostSubject